Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus
Authors:
- 15 March 2021
- journal article
- case report
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (3) , 299-301
Abstract
Pemphigus foliaceous (PF) is a pustular, immune‐mediated skin disease characterised by acantholytic cells and commonly treated with high doses of glucocorticoids. This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases.Keywords
This publication has 12 references indexed in Scilit:
- Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogsVeterinary Dermatology, 2020
- A pharmacokinetic study of oclacitinib maleate in six catsVeterinary Dermatology, 2019
- The role of oclacitinib in the management of ischaemic dermatopathy in four dogsVeterinary Dermatology, 2019
- Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987–2017)Veterinary Dermatology, 2019
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune DiseasesBioDrugs, 2019
- Feline pemphigus foliaceus: original case series and a comprehensive literature reviewBMC Veterinary Research, 2019
- A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinibVeterinary Dermatology, 2017
- Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergyJournal of Veterinary Pharmacology and Therapeutics, 2014
- Dermatoses affecting desmosomes in animals: a mechanistic review of acantholytic blistering skin diseasesVeterinary Dermatology, 2009
- Glucocorticoids in the catVeterinary Dermatology, 2008